This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
This document presents the estimated incidence of bloodstream infections (BSI) with three key antibiotic-resistant bacteria, at country level in EU/EEA countries, using public data sources.
Increased numbers of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde, have been reported in the EU/EEA, the United Kingdom (UK) and the United States (US) since September 2022.
An increased reporting of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde has been ongoing in the European Union/European Economic Area (EU/EEA), the United Kingdom (UK), and the United States (US) since September 2022. This outbreak evolved rapidly during November and December 2022.
The overall aim of the protocol is to support the implementation of a PPS of HAIs and antimicrobial use in European long-term care facilities, to meet the abovementioned objectives for ECDC surveillance.
Directory of guidance on prevention and control of Carbapenem-resistant Enterobacteriaceae, published by ECDC, EU/EEA Member States, international and national agencies and professional societies